baricitinib
baricitinib is a pharmaceutical drug with 109 clinical trials. Currently 27 active trials ongoing. Historical success rate of 86.9%.
Success Metrics
Based on 53 completed trials
Phase Distribution
Phase Distribution
20
Early Stage
35
Mid Stage
45
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
82.8%
53 of 64 finished
17.2%
11 ended early
27
trials recruiting
109
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
Clinical Trials (109)
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Therapeutics for Moderate and Severe Dengue
Randomised Evaluation of COVID-19 Therapy
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Baricitinib for Post-HSCT Persistent Thrombocytopenia
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
Efficacy and Safety of Baricitinib in Sjogren's Syndrome
Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 109